Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non–small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non–small cell lung cancer

Published:2023-09 Issue: Volume: Page:
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Kumar Arvind,Srinivasan Deepti,Potter Alexandra L.,Mathey-Andrews Camille,Lanuti Michael,Martin Linda W.,Jeffrey Yang Chi-Fu

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference28 articles.

1. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

2. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial);Provencio;J Clin Oncol,2022

3. Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer;Provencio;N Engl J Med,2023

4. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N Engl J Med,2017

5. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Spigel;J Clin Oncol,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis;Lung Cancer;2024-08

2. Letter to editor response: "Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Controversies and Discussion";Clinical and Translational Oncology;2024-06-14

3. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study;Cancer Immunology, Immunotherapy;2024-05-07

4. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017;Lung Cancer;2024-04

5. Commentary: Neoadjuvant immunotherapy followed by lung cancer resection: Is the future already here?;The Journal of Thoracic and Cardiovascular Surgery;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3